Hematology Frontier

From January 16 to 18, 2026, the Working Meeting of the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Myeloma Expert Committee and the 2026 CSCO Academic Conference on Hematologic Malignancies were held in Haikou, China. During the meeting, Professor Bing Xu of the First Affiliated Hospital of Xiamen University systematically outlined a comprehensive new framework for follicular lymphoma (FL), spanning precision risk stratification, therapeutic decision-making, and future research directions. His presentation provided valuable guidance for clinicians seeking to optimize treatment strategies and anticipate future developments in the field.

Aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome that poses significant clinical challenges due to marked patient heterogeneity, a high proportion of relapsed or refractory cases, and limited options for precision-based interventions. From January 9 to 11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was grandly held in Tianjin. The conference brought together leading hematology experts from China and abroad, focusing on cutting-edge scientific advances and national health strategy priorities, fostering in-depth academic exchange and exploration of future directions in the field.

The “Tianjin Model” of hematopoietic stem cell transplantation (HSCT) is a distinctive transplant system that integrates standardization, precision, and innovation. It has been progressively developed through nearly four decades of continuous exploration and generational knowledge transfer at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (also known as the Tianjin Institute of Hematology).

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) was recently successfully held in Orlando, United States. As the year’s flagship event in hematology, the meeting presented a concentrated series of groundbreaking advances in lymphoma research, offering new directions for the optimization of clinical practice.

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health priorities. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Zhijian Xiao from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into recent advances in precision risk stratification for myelodysplastic syndromes (MDS) and emerging targeted and immunotherapeutic strategies, highlighting the growing clinical importance of molecular classification in treatment decision-making.

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to explore cutting-edge advances in hematology aligned with national health strategies. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to provide in-depth insights into breakthroughs in FLT3 and IDH1/2 targeted therapy, precision strategies for elderly and high-risk AML populations, and MRD-guided dynamic treatment approaches, offering valuable perspectives for clinical practice and translational research.

From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading experts to discuss cutting-edge advances in hematology and national health priorities. During the conference, Oncology Frontier – Hematology Frontier invited Professor Lanping Xu from Peking University People’s Hospital to share her team’s latest progress in hematopoietic stem cell transplantation (HSCT) for severe aplastic anemia (SAA), with a focus on long-term outcomes of haploidentical transplantation, as well as optimization of transplant timing, patient stratification, and donor selection.

As an emerging modality of hematopoietic stem cell transplantation, umbilical cord blood transplantation (UCBT) has demonstrated unique clinical value in the treatment of various hematologic diseases. From January 9–11, 2026, the 6th China Hematology Discipline Development Conference (CASH) was held in Tianjin, bringing together leading hematology experts from China and abroad to explore cutting-edge research and national health priorities. During the conference, Professor Zimin Sun from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, shared in-depth insights into the current clinical status, technical advantages, and evolving research landscape of UCBT.

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the meeting, Professor Wei Xu from Jiangsu Provincial People’s Hospital provided a comprehensive review of key advances in CLL treatment, therapeutic decision-making in high-risk disease, and future research directions, offering valuable insights for optimizing clinical practice.